Cytokine Hemoadsorption in ECMO Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04901338

Enrollment

Registered

2021-05-25

Start date

2017-06-01

Completion date

2021-01-31

Last updated

2021-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS, Human, Cardiac Arrest, Cardiogenic Shock, Cytokine Storm, Septic Shock, SIRS

Keywords

Hemoadsorption, ECMO, SIRS, ARDS, Post-resuscitation syndrome, ECPR

Brief summary

Cytokine hemoadsorption is a novel therapy used to improve outcome in critically ill patients with a dysregulated cytokine response and hemodynamic instability. Patients on extracorporeal membraneous oxygenation (ECMO) often develop severe systemic inflammatory response syndrome (SIRS). Cytokine removal using different types of hemoadsorption devices is believed to block the vicious circle of inflammation dysregulation when other basic therapeutic measures fail. To date there are very limited reports on ECMO and cytokine hemoadsorption combination therapy. The aim of this retrospective study is to evaluate feasibility and effectiveness of hemoadsorption in veno-arterial and veno-venous ECMO patients.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* VA/VV ECMO * hemoadsorption * Age ≥ 18 years

Exclusion criteria

* no additional

Design outcomes

Primary

Measure	Time frame	Description
Haemodynamic stabilization	Within 12 hours after hemoadsorption	Decreased need for vasopressors according to vasoactive-inotropic score and increase in mean arterial pressure

Secondary

Measure	Time frame
Lactate, interleukin-6, C-reactive protein and procalcitonin clearance	Within 12 hours after hemoadsorption
Weaning from ECMO	from day of ECMO-implant for every 24 hours until date of weaning or death, whichever came first, assessed up to 90 days
ICU length of stay	from day of ICU-admission for every 24 hours until date of discharge or death, whichever came first, assessed up to 90 days
Hospital mortality	from day of hospital admission until date of discharge or death, whichever came first, assessed up to 90 days

Countries

Slovenia

Outcome results